PT - JOURNAL ARTICLE AU - KAZUKI SONE AU - TETSUYA OGURI AU - MAKOTO NAKAO AU - YUSUKE KAGAWA AU - RYOTA KUROWAKA AU - HIROMI FURUTA AU - SATOSHI FUKUDA AU - TAKEHIRO UEMURA AU - OSAMU TAKAKUWA AU - YOSHIHIRO KANEMITSU AU - HIROTSUGU OHKUBO AU - MASAYA TAKEMURA AU - KEN MAENO AU - YUTAKA ITO AU - HIDEFUMI SATO AU - HIDEKI MURAMATSU AU - AKIO NIIMI TI - CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy DP - 2017 Feb 01 TA - Anticancer Research PG - 935--939 VI - 37 IP - 2 4099 - http://ar.iiarjournals.org/content/37/2/935.short 4100 - http://ar.iiarjournals.org/content/37/2/935.full SO - Anticancer Res2017 Feb 01; 37 AB - Background: Pretreatment serum tumor marker levels predict outcome in non-small cell lung cancer (NSCLC). However, little is known about the clinical value of such measurements for patients treated with pemetrexed plus a platinum-derivative. Patients and Methods: We retrospectively screened 100 chemotherapy-naïve patients with advanced non-squamous NSCLC treated with pemetrexed plus a platinum-derivative in relation to the pretreatment level of cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA). Results: Sixty one patients with a high CYFRA 21-1 level had statistically shorter progression-free and overall survival than 39 patients with a normal CYFRA 21-1 level (median progression-free survival=127 days vs. 191 days, respectively; p=0.046; median overall survival=360 days vs. 781 days, respectively, p<0.001). Serum CEA level was not related to survival. Conclusion: Serum CYFRA 21-1 level is a predictive and prognostic marker in patients with NSCLC treated with pemetrexed plus a platinum-derivative.